There is no dispute with what you say. However Big Pharma as purchaser is free to pursue autism with NNZ-2591 should it decide. 1% of the US populace has autism. That is a market of 3.33 million people. Assume 30% uptake over time at $10k a year and revenues are at $10 billion per annum. Shazam!
There is no dispute with what you say. However Big Pharma as...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.94 |
Change
0.000(0.00%) |
Mkt cap ! $2.037B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 467 | $16.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.62 | 144 | 1 |
View Market Depth
| Last trade - 09.52am 14/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable